Background/Aims: Chronic kidney disease (CKD) is common in the general population, may lead to end-stage renal disease, and is most frequently found among males. Familial clustering of kidney diseases has been observed. We aimed to study a potential association between the family history of myocardial infarction (MI) and renal dysfunction. Methods:22,297 males and 10,828 females, aged 33-60 years, from a population-based cohort study were studied. Estimated glomerular filtration rate (eGFR) was assessed by the CKD-EPI creatinine equation. Every participant filled in a self-administered questionnaire including family history. Heredity for MI was defined as mother or father having had MI and/or died from MI, and/or brother or sister having had MI. Binary logistic regression and multiple linear regression were used in the analyses. Results: Multiple linear regression revealed a significantly increased risk of renal dysfunction in those with a positive heredity for MI (the whole cohort p = 0.01, males p = 0.000, females p = 0.169). Binary logistic regression showed that males with heredity for MI with a mean age of 43 years have a 2 times higher risk (p = 0.02) of belonging to the group with GFR <45 ml/min/1.73 m2 compared to those without heredity. For the whole cohort the increased risk was 1.6 times (p = 0.07). There was no significant association for females (p = 0.88). Conclusion: These findings demonstrate that a familial burden of MI is associated with renal dysfunction, in men, already in middle age. Genetic variants may underlie predisposition to CKD in those with heredity for MI.

Keywords:
Chronic kidney disease, Glomerular filtration rate, Heredity, Myocardial infarction
1.
Coresh J, Selvin E, Stevens L, Manzi J, Kusek J, Eggers P, Van Lente F, Levey A: Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-2047.
2.
US Renal Data System: USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and ESRD in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009.
3.
Swedish Renal Registry (SRR): www.snronline.se/. Sveriges kommuner och landsting.
4.
Hallan SI, Coresh J, Astor BC, Åsberg A, Powe N, Romundstad S, Hallan H, Lydersen S, Holmen J: International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006;17:2275-2284.
5.
Sarnak M, Levey A, Schoolwerth A, Coresh J, Culleton B, Hamm L, McCullough P, Kasiske B, Kelepouris E, Klag M, Parfrey P, Pfeffer M, Spinosa D, Wilson P: Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-2169.
6.
Ritz E: Minor renal dysfunction: an emerging independent cardiovascular risk factor. Heart 2003;89:963-964.
7.
Christensson A, Savage C, Sjoberg D, Cronin A, O'Brien F, Lowrance W, Nilsson P, Vickers A, Russo P, Lilja H: Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years. Int J Cancer 2013;133:1452-1458.
8.
Ronco C, Haapio M, House A, Anavekar N, Bellomo R: Cardiorenal syndrome. J Am Coll Cardiol 2008;52:1527-1539.
9.
Schrier R: Cardiorenal versus renocardiac syndrome: is there a difference? Nat Clin Pract Nephrol 2007;3:637.
10.
Jee SH, Boulware LE, Guallar E, Suh I, Appel LJ, Miller ER III: Direct, progressive association of cardiovascular risk factors with incident proteinuria: results from the Korea Medical Insurance Corporation (KMIC) study. Arch Intern Med 2005;165:2299-2304.
11.
Korstanje R, DiPetrillo K: Unraveling the genetics of chronic kidney disease using animal models. Am J Physiol Renal Physiol 2004;287:F347-F352.
12.
Perneger TV, Whelton PK, Klag MJ: Race and end-stage renal disease. Socioeconomic status and access to health care as mediating factors. Arch Intern Med 1995;155:1201-1208.
13.
Freedman B, Murea M: Target organ damage in African-American hypertension: role of APOL1. Curr Hypertens Rep 2012;1:21-28.
14.
Satko S, Sedor J, Iyengar S, Freedman B: Familial clustering of chronic kidney disease. Semin Dial 2007;20:229-236.
15.
Lei H, Perneger T, Klag M: Familial aggregation of renal disease in a population-based case-control study. J Am Soc Nephrol 1998;9:1270-1276.
16.
Arnett D, Baird A, Barkley R, Basson C, Boerwinkle E, Ganesh S, Herrington D, Hong Y, Jaquish C, McDermott D, O'Donnell C: Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2007;115:2878-2901.
17.
Kullo I, Ding K: Mechanisms of disease: the genetic basis of coronary heart disease. Nat Clin Pract Cardiovasc Med 2007;4:558-569.
18.
Fujimaki T, Kato K, Yoshida T, Oguri M, Watanabe S, Metoki N, Yoshida H, Satoh K, Aoyagi Y, Nishigaki Y, Tanaka M, Nozawa Y, Kimura G, Yamada Y: Association of genetic variants with myocardial infarction in Japanese individuals with chronic kidney disease. Thromb Haemost 2009;101:963-968.
19.
Berglund G, Eriksson KF, Israelsson B, Kjellström T, Lindgärde F, Mattiasson I, Nilsson JÅ, Stavenow L: Cardiovascular risk groups and mortality in an urban Swedish male population: the Malmö Preventive Project. J Intern Med 1996;239:489-497.
20.
Berglund G, Nilsson P, Eriksson KF, Nilsson JA, Hedblad B, Kristenson H, Lindgarde F: Long-term outcome of the Malmo Preventive Project: mortality and cardiovascular morbidity. J Intern Med 2000;247:19-29.
21.
Levey A, Stevens L, Schmid C, Zhang Y, Castro A 3rd, Feldman H, Kusek J, Eggers P, Van Lente F, Greene T, Coresh J: CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Int Med 2009;150:604-612.
22.
Cockroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
23.
duBois D, duBois EF: A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;17:863-871.
24.
National Kidney Foundation: KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(suppl 1):S1-S266.
25.
Levey AS, Coresh J, Greene T, Stevens L, Zhang Y, Hendriksen S, Kusek J, Van Lente F: Using standardized serum creatinine values in the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254.
26.
Nora J, Lortscher R, Spangler R, Nora A, Kimberling W: Genetic-epidemiologic study of early-onset ischemic heart disease. Circulation 1980;61:503-508.
27.
Myocardial Infarction Genetics Consortium: Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009;41:334-341.
28.
Erdmann J, Grosshennig A, Braund P: New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet 2009;41:280-282.
29.
Helgadottir A, Thorleifsson G, Manolescu A: A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007;316:1491-1493.
30.
Samani N, Erdmann J, Hall A: Genome-wide association analysis of coronary artery disease. N Engl J Med 2007;357:443-453.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.